Syngene
Syngene International Limited, commonly referred to as Syngene, is a leading global contract research and manufacturing organisation headquartered in Bengaluru, India. Founded in 1993, Syngene has established itself as a key player in the biopharmaceutical industry, providing integrated research and development services to clients across the globe. With a strong presence in North America, Europe, and Asia, Syngene offers a diverse range of services, including drug discovery, development, and manufacturing. The company is renowned for its innovative approach, leveraging cutting-edge technologies to deliver high-quality solutions tailored to client needs. Syngene's commitment to excellence has earned it a prominent market position, with notable achievements in collaborations with major pharmaceutical companies. Its unique blend of scientific expertise and operational efficiency sets Syngene apart in the competitive landscape of life sciences.
DitchCarbon Score
How does Syngene's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Syngene's score of 64 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Syngene's reported carbon emissions
In 2024, Syngene International Limited reported total greenhouse gas emissions of approximately 66,530,000 kg CO2e for Scope 1, 12,961,000 kg CO2e for Scope 2 (market-based), and 48,768,000 kg CO2e for Scope 3 emissions. The combined Scope 1 and 2 emissions totalled about 19,614,000 kg CO2e. In comparison, the previous year, 2023, saw emissions of approximately 6,003,000 kg CO2e for Scope 1, 18,433,000 kg CO2e for Scope 2 (market-based), and 89,418,000 kg CO2e for Scope 3, with combined Scope 1 and 2 emissions at about 24,768,000 kg CO2e. Syngene has set ambitious climate commitments, aiming for a 50% reduction in Scope 1 and 2 emissions by 2033 from a 2023 baseline. Additionally, the company targets a 30% reduction in Scope 1 and 2 emissions by 2030 from a 2021 baseline. For Scope 3, Syngene plans to engage suppliers representing approximately 70% of emissions in the supply chain to adopt science-based targets by 2028. The company’s ESG Council is actively involved in reviewing and committing to these targets, with a focus on aligning with science-based methodologies to ensure compliance with climate goals. Syngene's initiatives reflect a strong commitment to addressing climate change and reducing its carbon footprint in the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 3,440,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 11,263,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 62,847,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Syngene is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
